AFTER BREAST CANCER DIAGNOSIS C.I.C.

Company limited by guarantee

Company Registration Number:
11174173 (England and Wales)

Unaudited statutory accounts for the year ended 30 January 2024

Period of accounts

Start date: 1 February 2023

End date: 30 January 2024

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Contents of the Financial Statements

for the Period Ended 30 January 2024

Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Balance sheet

As at 30 January 2024

Notes 2024 2023


£

£
Fixed assets
Tangible assets: 3 1,474 1,341
Total fixed assets: 1,474 1,341
Current assets
Cash at bank and in hand: 31,116 19,271
Total current assets: 31,116 19,271
Net current assets (liabilities): 31,116 19,271
Total assets less current liabilities: 32,590 20,612
Accruals and deferred income: ( 33,427 ) ( 21,383 )
Total net assets (liabilities): (837) (771)
Members' funds
Profit and loss account: (837) ( 771)
Total members' funds: ( 837) (771)

The notes form part of these financial statements

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Balance sheet statements

For the year ending 30 January 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 15 December 2024
and signed on behalf of the board by:

Name: J Taylor
Status: Director

The notes form part of these financial statements

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Notes to the Financial Statements

for the Period Ended 30 January 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Notes to the Financial Statements

for the Period Ended 30 January 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 1 1

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Notes to the Financial Statements

for the Period Ended 30 January 2024

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 February 2023 2,383 2,383
Additions 199 199
Disposals
Revaluations
Transfers
At 30 January 2024 2,582 2,582
Depreciation
At 1 February 2023 1,042 1,042
Charge for year 66 66
On disposals
Other adjustments
At 30 January 2024 1,108 1,108
Net book value
At 30 January 2024 1,474 1,474
At 31 January 2023 1,341 1,341

COMMUNITY INTEREST ANNUAL REPORT

AFTER BREAST CANCER DIAGNOSIS C.I.C.

Company Number: 11174173 (England and Wales)

Year Ending: 30 January 2024

Company activities and impact

The companies aim is to support people that have been diagnosed, being treated for, or are recovering from cancer. Throughout the year a number of 2-3-day events are organised to bring together people affected for support, advice and companionship. The events focus on is for people to experience and receive motivation, exercise, strength, support, help, share experiences, meet new friends, get time away from day to day normal life and get out in the fresh air. All this is to help and support people through their cancer journey. The company aims to receive income from grants which will fully fund or at least subsidise the cost to attendees.

Consultation with stakeholders

Stakeholders are consulted by means of feedback from sources such as twitter support groups and also consulting relevantly qualified professionals such as doctors and nurses and their views are listened to and acted upon.

Directors' remuneration

The director was paid £6,000 during the year.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
15 December 2024

And signed on behalf of the board by:
Name: J Taylor
Status: Director